Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Mar 14, 2018 20:12 UTC |
Dodson Edward TPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011543 · form4.xml · nonDerivative · entry 1 Dodson Edward T · CIK 0001620889 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,971.9891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 24 and 42 shares that were inadvertently omitted from the reporting person's original Forms 4 filed on April 9, 2018 and April 13, 2018, respectively, due to a clerical error. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:47 UTC |
KING DAVID PDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011532 · form4.xml · derivative · entry 5 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,524 Underlying: Common Stock · 6,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:47 UTC |
KING DAVID PDirector · President & CEO
|
Tax withholdingCommon Stock | 2,732 | $175.61 | $479,766.52 |
DisclosureSEC source: 0001127602-18-011532 · form4.xml · nonDerivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,235.3298 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:47 UTC |
KING DAVID PDirector · President & CEO
|
Exercise / conversionCommon Stock | 6,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011532 · form4.xml · nonDerivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,967.3298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:38 UTC |
EBERTS F SAMUEL IIIChief Legal Officer, Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 464 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011531 · form4.xml · derivative · entry 3 EBERTS F SAMUEL III · CIK 0001229291 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,814 Underlying: Common Stock · 464 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:38 UTC |
EBERTS F SAMUEL IIIChief Legal Officer, Secretary
|
Tax withholdingCommon Stock | 129 | $175.61 | $22,653.69 |
DisclosureSEC source: 0001127602-18-011531 · form4.xml · nonDerivative · entry 2 EBERTS F SAMUEL III · CIK 0001229291 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,619 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:38 UTC |
EBERTS F SAMUEL IIIChief Legal Officer, Secretary
|
Exercise / conversionCommon Stock | 464 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011531 · form4.xml · nonDerivative · entry 1 EBERTS F SAMUEL III · CIK 0001229291 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:30 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011528 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,791 Underlying: Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/16 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/16 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:30 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 120 | $175.61 | $21,073.20 |
DisclosureSEC source: 0001127602-18-011528 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,709 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:30 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionCommon Stock | 400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011528 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:33 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011529 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,204 Underlying: Common Stock · 1,627 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on 3/11/2016 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:33 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 732 | $175.61 | $128,546.52 |
DisclosureSEC source: 0001127602-18-011529 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,726 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:33 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 1,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011529 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:28 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 537 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011526 · form4.xml · derivative · entry 3 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,028 Underlying: Common Stock · 537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Unit vested in three equal installments beginning on 3/11/2016 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Unit vested in three equal installments beginning on 3/11/2016 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:28 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Tax withholdingCommon Stock | 184 | $175.61 | $32,312.24 |
DisclosureSEC source: 0001127602-18-011526 · form4.xml · nonDerivative · entry 2 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,589.6826 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:28 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
Exercise / conversionCommon Stock | 537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-011526 · form4.xml · nonDerivative · entry 1 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,773.6826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:34 UTC |
KING DAVID PDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 41,000 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-006010 · form4.xml · derivative · entry 2 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2028-02-11 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:34 UTC |
KING DAVID PDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 10,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006010 · form4.xml · derivative · entry 1 KING DAVID P · CIK 0001275654 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,601 Underlying: Common Stock · 10,540 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006007 · form4.xml · derivative · entry 5 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,831 Underlying: Common Stock · 2,340 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F7 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F8 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 9,100 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-006007 · form4.xml · derivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-02-11 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 500 | $168.61 | $84,307.00 |
DisclosureSEC source: 0001127602-18-006007 · form4.xml · nonDerivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,831 F3 · price: The price of $168.6140 per share represents a weighted average of sales prices ranging from $168.59 to $168.68 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 1,600 | $167.78 | $268,444.00 |
DisclosureSEC source: 0001127602-18-006007 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,331 F2 · price: The price of $167.7775 per share represents a weighted average of sales prices ranging from $167.59 to $168.58 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
SaleCommon Stock | 6,300 | $167.16 | $1,053,089.10 |
DisclosureSEC source: 0001127602-18-006007 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,931 F1 · price: The price of $167.1570 per share represents a weighted average of sales prices ranging from $166.58 to $167.53 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:31 UTC |
Caveney Brian JSVP, Chief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006002 · form4.xml · derivative · entry 2 Caveney Brian J · CIK 0001717915 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,670 Underlying: Common Stock · 700 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:31 UTC |
Caveney Brian JSVP, Chief Medical Officer
|
GrantNon-qualified Stock Options · Derivative | 2,700 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-006002 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:28 UTC |
EBERTS F SAMUEL IIIChief Legal Officer, Secretary
|
GrantRestricted Stock Unit · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005997 · form4.xml · derivative · entry 2 EBERTS F SAMUEL III · CIK 0001229291 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,278 Underlying: Common Stock · 700 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:28 UTC |
EBERTS F SAMUEL IIIChief Legal Officer, Secretary
|
GrantNon-qualified Stock Options · Derivative | 2,700 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005997 · form4.xml · derivative · entry 1 EBERTS F SAMUEL III · CIK 0001229291 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:27 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 770 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005994 · form4.xml · derivative · entry 2 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565 Underlying: Common Stock · 770 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:27 UTC |
Uthgenannt Lisa JChief Human Resources Officer
|
GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005994 · form4.xml · derivative · entry 1 Uthgenannt Lisa J · CIK 0001636456 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:25 UTC |
Ratliff John DCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 4,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005993 · form4.xml · derivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,217 Underlying: Common Stock · 4,390 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:25 UTC |
Ratliff John DCEO, Covance Drug Development
|
GrantNon-qualified Stock Options · Derivative | 17,100 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005993 · form4.xml · derivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:24 UTC |
Dodson Edward TPrincipal Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 590 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005992 · form4.xml · derivative · entry 2 Dodson Edward T · CIK 0001620889 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,934 Underlying: Common Stock · 590 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:24 UTC |
Dodson Edward TPrincipal Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 2,300 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005992 · form4.xml · derivative · entry 1 Dodson Edward T · CIK 0001620889 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:23 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
GrantRestricted Stock Unit · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005990 · form4.xml · derivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191 Underlying: Common Stock · 700 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:23 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
GrantNon-qualified Stock Options · Derivative | 2,700 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005990 · form4.xml · derivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:21 UTC |
Gary M. HuffCEO, LabCorp Diagnostics
|
GrantRestricted Stock Unit · Derivative | 1,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005988 · form4.xml · derivative · entry 2 Gary M. Huff · CIK 0001702387 · CEO, LabCorp Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,721 Underlying: Common Stock · 1,760 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 19:21 UTC |
Gary M. HuffCEO, LabCorp Diagnostics
|
GrantNon-qualified Stock Options · Derivative | 6,800 | $0.00 Strike: $168.49 | $0.00 |
DisclosureSEC source: 0001127602-18-005988 · form4.xml · derivative · entry 1 Gary M. Huff · CIK 0001702387 · CEO, LabCorp Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2028-02-11 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:15 UTC |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005651 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:14 UTC |
Schechter Adam HDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005650 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:12 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005648 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:11 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005646 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:09 UTC |
MITTELSTAEDT ROBERT E JRDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005644 · form4.xml · derivative · entry 1 MITTELSTAEDT ROBERT E JR · CIK 0001200847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:08 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005642 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:07 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005641 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:05 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005640 · form4.xml · derivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:04 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005639 · form4.xml · derivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC |
Ratliff John DCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · derivative · entry 5 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,827 Underlying: Common Stock · 6,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC |
Ratliff John DCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 2,132 | $168.08 | $358,346.56 |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · nonDerivative · entry 2 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,398 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 19:08 UTC |
Ratliff John DCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 6,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-005415 · form4.xml · nonDerivative · entry 1 Ratliff John D · CIK 0001575951 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 18:58 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 3,300 | $0.00 Strike: $75.63 | $0.00 |
DisclosureSEC source: 0001127602-18-005411 · form4.xml · derivative · entry 3 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,300 shares Expires 2018-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F2 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.